$230 Million

Krystal Biotech

Follow-on Offering

Bookrunner, November 2021

Krystal Biotech, Inc. (the “Company” or “Krystal”) is a clinical-stage biotechnology company leading the field of redosable gene delivery for the treatment of serious rare diseases. The Company uses its patented platform that is based on engineered HSV-1, to create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the encoded effector to treat or prevent disease. The lead product candidate, beremagene geperpavec (previously KB103), now known as VYJUVEK, is a topical gene therapy to treat dystrophic epidermolysis bullosa, a rare and severe monogenic skin disease for which there may not be a treatment to affect the outcome of the disease.

More Like This

Dec 2021
$295.7 Million

Follow-on Offering

Bookrunner

View Details
Nov 2021
$115.3 Million

Follow-on Offering

Lead Left Bookrunner

View Details
Nov 2021
$115.9 Million

Follow-on Offering

Lead Left Bookrunner

View Details